Search Drug Information, Interactions, Images, Dosage & Side Effects

Smoking cessation intervention during lung screening may encourage quitting 05 Dec 2022

A smoking cessation intervention, introduced as part of lung health screening, may encourage quitting in about 30 percent of smokers, results of the UK-based YESS* trial showed.

Anti-Xa levels useful for therapy safety, drug concentration assessment

05 Dec 2022

Hydrogen intake eases breath alcohol levels, hangover symptoms

05 Dec 2022

Dose reduction necessary in some HFrEF patients on sacubitril-valsartan

05 Dec 2022

Dip in serum cholesterol tied to higher pancreatic cancer risk

05 Dec 2022

Adding salt to foods ups CVD risk

04 Dec 2022

Pharmacist-led smoking cessation program prompts quit attempts, IBD medication use

04 Dec 2022

Post-PCI bivalirudin infusion reduces death, bleeding vs heparin

04 Dec 2022

Group CBT may help improve emotion regulation in adults with autism

04 Dec 2022

HCV, HBV coinfection does not compromise HIV prognosis in the presence of active ART

04 Dec 2022

Fatty liver more common in MAFLD than NAFLD

03 Dec 2022

New Treatment Options for Multiple Myeloma Improves Patients’ Overall Survival, Quality of Life 05 Dec 2022;
Multiple myeloma (MM) is a form of cancer where abnormal plasma cells, a type of white blood cell, accumulate in the bone marrow and replace the normal, healthy cells. While healthy plasma cells produce antibodies, cancerous plasma cells produce abnormal proteins, and the by-products of these proteins cause complications. New treatment options have transformed MM from an acute disease with a median survival of <6 months to a chronic condition where patients have better survival and quality of life (QOL).

Targeting the right patients in treatment of severe eosinophilic asthma and bringing balance to their lives.

05 Dec 2022

MANAGING INFECTIONS AMONG PATIENTS WITH MULTIPLE MYELOMA

05 Dec 2022

ATTR-ACT LONG-TERM EXTENSION STUDY POINTS TO BETTER SURVIVAL OUTCOMES WITH TAFAMIDIS

01 Dec 2022

Roxatin

Contents : Rosuvastatin Ca

Indications/Uses : Adjunct to diet for reduction of elevated total cholesterol (total-C), LDL-C, Apo B, total-C: HDL-C ratio & triglycerides & for increasing HDL-C in hyper- & dyslipidemic conditions. Reduce total mortality & risk of major CV events in adults w/ increased risk of ASCVD based on presence of CV disease risk markers. Primary dysbetalipoproteinemia (type III hyperlipoproteinemia); primary hypercholesterolaemia [type IIa including heterozygous familial hypercholesterolaemia (HeFH) & severe non-familial hypercholesterolaemia]; combined (mixed) dyslipidemia (type IIb); HoFH. Adjunctive therapy to diet to slow progression of atherosclerosis in adults as part of treatment strategy to lower total-C & LDL-C to target levels. Adjunct to diet to reduce total-C, LDL-C & Apo B levels in adolescents at least 1 yr post-menarche, 10-17 yr w/ HeFH.

Idacio

Contents : Adalimumab

Indications/Uses : Adult: Monotherapy or in combination w/ MTX or other DMARDs in patients w/ moderate to severe active RA. Monotherapy or in combination w/ DMARDs in patients w/ active psoriatic arthritis. Active ankylosing spondylitis (AS). Non-radiographic axial spondyloarthritis (nr-axSpA) in patients w/ inadequate response to or are intolerant to NSAIDs. Moderate to severe chronic plaque psoriasis in patients who are candidates for systemic- or phototherapy & when other systemic therapies are medically less appropriate. Moderate to severe active Crohn's disease in patients w/ inadequate response to conventional therapy, or who have lost response to or are infliximab-intolerant. Moderate to severe active ulcerative colitis in patients w/ inadequate response to conventional therapy including corticosteroids &/or 6-mercaptopurine or azathioprine, or who are intolerant to, or have medical CI for such therapies. Active moderate to severe hidradenitis suppurativa (HS) in patients w/ inadequate response to conventional systemic HS therapy. Non-infectious intermediate, posterior & panuveitis in patients w/ inadequate response to corticosteroids, in need of corticosteroid-sparing or in whom corticosteroids is inappropriate. Ped: Monotherapy or in combination w/ MTX for active polyarticular juvenile idiopathic arthritis (pJIA) in patients >2 yr w/ inadequate response to ≥1 DMARDs. Active enthesitis-related arthritis in patients ≥6 yr w/ inadequate response to or who are intolerant of conventional therapy. Moderate to severe active Crohn's disease in ped patients 6-17 yr w/ inadequate response to conventional therapy eg, primary nutrition therapy, corticosteroids &/or immunomodulator, or who are intolerant to or have CI for such therapies. Severe chronic plaque psoriasis in childn & adolescents from 4 yr w/ inadequate response to or are inappropriate candidates for topical- & phototherapy. Chronic non-infectious anterior uveitis in patients from 2 yr w/ inadequate response to or are intolerant to conventional therapy, or in whom conventional therapy is inappropriate. Active moderate to severe HS in adolescents from 12 yr w/ inadequate response to conventional systemic HS therapy.

Cruzor

Contents : Irbesartan

Indications/Uses : Essential HTN. Diabetic nephropathy w/ elevated serum creatinine & proteinuria (>300 mg daily) in patients w/ type 2 diabetes & HTN.

Ravida

Contents : Ravidasvir

Indications/Uses : In combination w/ other medicinal products for adults w/ chronic HCV infection.

Talzenna

Contents : Talazoparib

Indications/Uses : Monotherapy for adults w/ germline BRCA1/2-mutations, HER2 -ve locally advanced or metastatic breast cancer previously treated w/ anthracycline &/or taxane in the neoadjuvant, locally advanced or metastatic setting unless unsuitable. Patients w/ hormone-receptor +ve breast cancer should have been treated w/ prior or be considered unsuitable for endocrine-based therapy.

Amnoz

Contents : Amlodipine

Indications/Uses : 1st-line treatment of HTN, myocardial ischemia whether due to fixed obstruction (stable angina) &/or vasospasm/vasoconstriction (Prinzmetal's or variant angina) of coronary vasculature.